SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet shares are rallying as the market shifts from questioning AI capital expenditure to rewarding hyperscalers for accelerating cloud revenue growth and deepening enterprise AI integration. Investors are increasingly focused on Google's massive backlog and infrastructure scaling, signaling a move toward viewing these heavy investments as long-term growth engines rather than mere expenses.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing heightened volatility and intense community debate as investors weigh the impact of rising competition from prediction markets and anticipation surrounding upcoming earnings. The stock is currently a battleground between long-term bulls betting on football season engagement and vocal bears who remain skeptical of the company's valuation and market leadership.

Alphabet Inc - Ordinary Shares - Class C

Alphabet shares are facing volatility as the market digests the departure of key AI leadership alongside concerns over the company's massive capital expenditure plans for AI infrastructure. While some investors view the pullback as a buying opportunity given Google's strong cloud performance and deep bench of talent, others remain cautious about potential project delays and the long-term ROI of the company's aggressive investment cycle.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is experiencing significant volatility following reports that Waymo is exploring an end to their robotaxi partnership, fueling concerns about the company's autonomous vehicle strategy and long-term control over the mobility market. Despite the sell-off, community discussions remain divided between those viewing the pullback as a buying opportunity given Uber's strong free cash flow and market dominance, and others who are frustrated by the stock's persistent underperformance and lack of clear strategic direction.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending following a better-than-expected earnings report that beat revenue and earnings forecasts, triggering a sharp post-market rally. The community is actively debating whether this represents a sustainable turnaround driven by subscription growth and advertising momentum or if it is merely a volatile 'dead cat bounce' amidst concerns over leadership, share dilution, and the long-term viability of their hardware investments.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is attracting significant institutional interest as central banks, particularly China, continue their aggressive accumulation strategy while the asset benefits from safe-haven inflows amid heightened geopolitical tensions and persistent fiscal concerns. Investors are closely monitoring the breakout above key moving averages, with community sentiment shifting toward a potential long-term trend reversal as macroeconomic factors like elevated debt and fiscal deficits gain prominence in market discussions.

Shake Shack, Inc. engages in the operation and licensing of Shake Shack restaurants which serve burgers, hot dogs, crinkle cut fries, shakes, frozen custard, beer, wine, and related products. The company was founded by Daniel Harris Meyer on September 23, 2014 and is headquartered in New York, NY.

Shake Shack Inc - Ordinary Shares - Class A

Shake Shack is seeing significant volatility as investors react to a downward revision in quarterly guidance and missed profit expectations driven by rising costs and regional disruptions. The community remains divided between those capitalizing on the sharp dip as a long-term value play and others raising concerns over the company's high valuation and competitive pressures within the restaurant sector.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is experiencing heightened investor interest driven by strong organic growth, cost-cutting initiatives, and ongoing market speculation regarding a potential buyout or acquisition. While community members debate whether to hold for a longer-term valuation expansion or profit from potential M&A activity, the stock remains a focal point for those monitoring sector-wide consolidation.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently a focal point for investors as they monitor potential share price volatility ahead of their upcoming quarterly earnings, while also processing the termination of the Eli Lilly RIPK1 collaboration. The community remains deeply divided, with some investors accumulating shares based on fundamental growth in Tavalisse and Rezlidhia, while others express frustration over the stock's stagnant price action and persistent short interest.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently the focus of intense market speculation as investors weigh strong revenue growth and aggressive AI infrastructure spending against a massive upcoming unlock of insider shares. The community is sharply divided, with bulls pointing to the company's long-term dominance in satellites and compute, while bears are preparing for potential volatility driven by increased float and insider selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective...

Evommune Becomes Oversold (EVMN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, July 7, 2026 Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous...

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) PR Newswire NEW YORK, June 30, 2026 Evommune's CEO and...

EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal

Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.

This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Wall Street analysts changed outlook on top names, including Alphine Income Property Trust, AAR Corp, and Evommune. See analyst ratings for these stocks.read more...

Evommune's Skin Disorder Study Falls Short

Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.read more...

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Evommune, Inc. (NYSE: EVMN) (the Company or Evommune), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial...

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced...

Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell

Wall Street Zen downgraded Evommune from a "hold" rating to a "sell" rating in a research report on Saturday...

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.21
Prev Close	$13.11
Open	$13.05
Dividend Yield	0.00%
50-Day Moving Average	$16.84
Beta	0.91
Avg. Volume	780,704.54
PE Ratio	-5.49

52-Week High	$33.20
52-Week Low	$10.47
Market Capitalization	$472.2M
EPS (Annual)	-$2.18
Price to Book	1.55
Revenue Per Employee	$270,833.33

Feed

News

Sentiment

Fundamentals

Info